A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects

Condition:   Healthy Subjects Interventions:   Drug: Vorasidenib 40 mg Oral Tablet;   Drug: Ciprofloxacin 500 mg Oral Tablet;   Drug: Vorasidenib 10 mg Oral Tablet Sponsors:   Servier Bio-Innovation LLC;   Institut de Recherches Internationales Servier Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials